Trial · NCT00819637
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Averaged Mean Percent Change From Baseline FEV1 and PEFR (Percent Predicted and Absolute) After the 3 Doses of Study Drug | 1 hour | |
| Secondary | Most Effective Dose of Inhalation Arformoterol for Treating Acute Bronchospasm in Asthmatics by Evaluating the Averaged Mean Percent Change From Baseline % Predicted FEV1 After 3 Doses of Study Medication in Each of the 3 Groups | 1 hour | The study was terminated early and therefore secondary outcome measures were not obtained. |
| Secondary | Number of Participants Treated With Arformoteral in Acute Asthma Exacerbation as a Measure of Safety and Tolerability. | 5 hours | The study was terminated early and therefore secondary outcome measures were not obtained. |
| Secondary | The Mean Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug | 1 hour | |
| Secondary | The Mean Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug | 1 hour | The study was terminated early and therefore secondary outcome measures were not obtained. |
| Secondary | The Peak Change (Liters) and Peak Percent Change From Baseline in the FEV1 and PEFR (Absolute and Percent Predicted) Following Each Dose of Study Drug | 1 hour | |
| Secondary | The Time to Onset of a 15% Improvement in FEV1 for Each Dose (Individual and Cumulative) and Total Dose of Study Medication to Reach This | 5 hour | |
| Secondary | The Time Required to Achieve a FEV1 and PEFR > 60% Predicted for Each Dose (Individual and Cumulative) | 5 hours | |
| Secondary | Percent of Responders (Defined as Those Discharged Following Treatment Who Did Not Require Additional Therapy in the ED) | 5 hours | The 2 subjects enrolled were both discharged home after study protocol completion, with no further treatment required in the ED setting. |
| Secondary | Percent of Patients in Each Group Requiring Additional Therapies After the First Hour of Study Drug Treatments | 5 hours | 2 subjects were enrolled. Neither required additional asthma treatment after the 1st hour of study drug teatments. |
| Secondary | All of the Primary and Secondary Endpoints Partitioned by the Presenting PFT in Quartiles and the Presenting S Albuterol Levels in Quartiles | 5 hours | |
| Secondary | Pharmacokinetics of Arformoterol in This Clinical Setting | 5 hours |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00819637/registered